Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An MVA vaccine for delivery of a UL128 complex and preventing CMV infection

The technology of a kind of construct and viral vector, applied in the field of vaccine composition for preventing HCMV from invading cells, treating HCMV infection, and preventing HCMV infection

Pending Publication Date: 2019-09-17
CITY OF HOPE
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there are no approved vaccines to prevent HCMV infection and / or disease, however, the Institute of Medicine of the National Academy of Sciences issued a report in 2000, due to the improvements to human health that such a vaccine would bring and put the development of HCMV vaccine in the highest priority category

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
  • An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
  • An MVA vaccine for delivery of a UL128 complex and preventing CMV infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1: A Vaccine Introducing Broadly Neutralizing Antibodies in CMV Nascent Rhesus Monkeys that Inhibits the Main Entry Point of CMV Infection in Rhesus Monkeys

[0078] Viruses and cells. MVA propagation in baby hamster kidney (BHK) cells, and preparation and storage of virus stocks were performed according to previously reported protocols (Wang et al. 2010). Chicken embryonic fibroblasts (CEF) used for MVA propagation were maintained in serum-free medium for virus production (VP-SFM; Invitrogen).

[0079]MVA expressing a full-length pentamer of the five subunits RhUL128, RhUL130, RhUL131, RhgL, and RhgH (MVA-RhUL128C), with an alternate transmembrane (TM) site deletion, was generated by BAC technology as described below Versions of gH express the MVA of this 5-subunit pentamer (MVA-RhUL128C[Delta]), or the MVA of the RhUL128, RhUL130, and UL131A subunits. MVAs expressing RhUL128 or RhUL130 alone were generated by a routine protocol in eukaryotic cells as previou...

Embodiment 2

[0121] Example 2: Construction and expression of HCMV UL128C pentamer expressed from MVA

[0122] MVA expression of the human UL128C subunit. MVA expressing 5 subunit pentamers of full length human UL128, UL130, UL131, gL and gH (H-UL128C-MVA) was generated by BAC technique similar to Example 1.

[0123] like Figure 8 As shown, all five subunits of human UL128C (H-UL128C) were successfully expressed and individual subunits were detected by either mAb (gH, UL128, UL130) or polyclonal antisera (UL131A, gL). The MWs of the individual subunits are consistent with published data, providing strong evidence that MVA-based expression is accurate and reliable for the structure of these subunits expressed from HCMV. Figure 8 Compositions containing alternating gH structures (e.g., gH, gHΔTM lacking the transmembrane region) co-expressed with the other four H-UL128C subunits are shown (a composition with alternating gHΔTM is represented by UL128CΔ, and Full-length gH (gH-FL) is re...

Embodiment 3

[0125] Example 3: Construction and evaluation of clinically acceptable MVA-BAC for human use

[0126] Preclinical studies with RhCMV were facilitated by a previously constructed MVA-BAC vector (Cottingham 2008). All vaccines using RhCMV compounds use this MVA-BAC combination. However, because the origin of MVA is unknown, a different vaccine vector will be used for human use. The MVA MBA will also be constructed in such a way that vector sequences can be deleted after viral recombination to avoid retention of any unwanted functional bacterial sequences, a property that may be necessary for FDA approval. The vector components will be inserted into the TK site to recombine the insertion site for transgene expression. The construction of MVA-BAC for humans was followed by using the 1974-MVA provided by Dr. Bernard Moss of NIAID. The clinical use of MVA has allowed the development of a variety of vaccines, many of which are now entering clinical trials. Therefore, 1974-MVA s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM / gN or gO.

Description

[0001] This application is a divisional application of the Chinese invention patent application submitted on March 15, 2013, titled "A MVA Vaccine for Delivering UL128 Complex and Preventing CMV Infection", and the application number is 201380050859.7. [0002] Statement of Government Rights and Interests [0003] This invention was made with Government support under Grant No. AI063356 awarded by the National Institute of Allergy and Infectious Diseases (US) and CA030206 awarded by the National Cancer Institute (US). The US Government has certain rights in this invention. [0004] priority statement [0005] This application claims the benefit of priority to US Patent Provisional Application No. 61 / 676846, filed July 27, 2012, which is hereby incorporated by reference in its entirety. Background technique [0006] The cytomegalovirus (CMV) genome is large (greater than 200kbp), and the human cytomegalovirus (HCMV) encodes ≥165 open reading frames (ORFs), which encode protein...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/863
CPCC07K14/005A61K2039/5256C12N2710/16122C12N2710/16134C12N2799/023C12N2800/204A61K39/12A61K2039/5254A61K2039/70C12N2710/24143A61K39/245A61P31/12C12N7/00
Inventor 唐·J·戴蒙德费利克斯·乌索彼得·A·巴瑞
Owner CITY OF HOPE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com